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OUT WITH THE OLD, IN WITH THE NEW? 
Improving Clinical Outcome in Patients with Hypertrophic Obstructive 
Cardiomyopathy 
Elise Shellenberger & Elizabeth Thompson 
 
Abstract 
Objective: Review two studies that assess alcohol septal ablation (ASA) and surgical 
myectomy as treatment options for patients with drug refractory hypertrophic obstructive 
cardiomyopathy (HOCM).  Background: Controversy exists regarding these two forms 
of treatment for HCOM. Design: Two observational cohort studies. Methods: A search 
was done on PubMed, utilizing the terms “hypertrophic cardiomyopathy,” “alcohol septal 
ablation,” and “myectomy.” The following limits were used: published in the last 15 
years, humans, English, and comparative studies.  Results: Study One4 showed that the 
patients undergoing ASA had a lower periprocedural complication frequency compared 
to those undergoing myectomy (14% [22 of 161] versus 28% [29 of 102], p-value 0.004). 
Patients undergoing ASA also had a significantly shorter follow-up stay than those 
undergoing myectomy (5 days versus 9 days, p-value <0.001). Multivariate analysis 
showed that age was the only independent predictor of long-term mortality (hazard ratio 
1.34, 95% CI 1.08-1.65, p-value 0.007). Study Two5 showed that the resting pressure 
gradient (PG) was significantly decreased following both procedures (64 ± 39 mmHg to 
24 ± 19 mmHg for ASA, and 62 ± 43 mmHg to 11 ± 6 mmHg for myectomy, both p < 
0.0001) at 3-month follow up. The NYHA functional class was also significantly 
improved in both groups; ASA patients from 3.5 ± 0.5 to 1.9 ± 0.7, and myectomy 
patients from 3.3 ± 0.5 to 1.5 ± 0.7, both p-values < 0.0001). Conclusion: Both ASA and 
surgical myectomy provide comparable clinical outcomes in patients. ASA is associated 
with decreased hospital stay and less periprocedural complications. Surgical myectomy 
provides more complete reduction in pressure gradient, but is a more invasive procedure. 
ASA is a relatively new procedure therefore further studies will be helpful to validate it's 
efficacy in comparison to myectomy. 
Introduction 
Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial 
disorder and the most common cause of sudden death in young athletes. HCM affects 1 
out of every 500 people and is more common in men than women.1  The genetic 
mutations are passed in an autosomal dominant fashion and include defects in the cardiac 
sarcomere proteins. These defects cause enlarged heart muscle cells and thick ventricular 
walls resulting in abnormal diastolic function with impaired ventricular filling. The 
characteristic left ventricular hypertrophy (LVH) results in a resting or exercise provoked 
left ventricular outflow tract (LVOT) obstruction in 70% of patients. If the LVOT is 
obstructed, the condition is characterized as hypertrophic obstructive cardiomyopathy 
(HOCM)2. Any exercise that is strenuous enough to increase afterload will worsen the 
hypertrophy and therefore worsen the obstruction and symptoms. 
Dyspnea is the presenting symptom in 90% of HOCM patients. Other symptoms 
include chest pain, palpitations, dizziness, syncope, and sudden death. Additionally, 
patients can experience high blood pressure or arrhythmias due to disruption of the 
heart’s electrical signals. For patients who are still symptomatic despite the use of first 
line pharmacologic treatments such as beta blockers; surgical myectomy and alcohol 
septal ablation (ASA) are two procedures that can reduce the LVOT obstruction and 
improve New York Heart Association (NYHA) functional class.  
Surgical myectomy has been performed for decades and involves direct removal 
of the septal muscle. The removal of the hypertrophied muscle relieves the obstruction 
and increases the amount of blood able to leave the left ventricle thereby improving 
systolic function of the heart.  Complications of the procedure include a ventricular septal 
defect, a left bundle branch block, or complete heart block necessitating a permanent 
pacemaker. Because myectomy requires a thoracotomy, patients often desire a less 
invasive procedure. Alcohol septal ablation (ASA) is performed percutaneously as part of 
a cardiac catheterization. During the procedure, ethanol is injected into a branch of a 
septal perforator coronary artery to create a localized infarction and subsequent septal 
remodeling over time, which results in a reduction in myocardial mass and therefore, 
improved systolic function3. Complications of ASA include coronary artery dissection, 
large myocardial infarction, complete heart block, and ventricular tachyarrhythmias. ASA 
has also been associated with an increased risk of residual LVOT gradient due to non-
complete ablation, therefore requiring a repeat septal reduction procedure. 
 
Clinical Question & Scenario 
P. In patients with symptomatic hypertrophic obstructive cardiomyopathy 
I. Does alcohol septal ablation 
C. Compared to surgical myectomy 
O. Decrease symptoms and improve long term outcome 
 
A 55 year old male with diagnosed HOCM is severely symptomatic despite 
pharmacologic treatments. Is septal myectomy or alcohol ablation the best 
procedure for this patient? 
 
Methods 
An initial search of PubMed was performed in September 2015 using the terms 
hypertrophic cardiomyopathy, alcohol septal ablation, and myectomy. Limits included 
“published in the last 15 years,” “humans,” “comparative studies,” and “English”. This 
yielded 13 articles. Ultimately, two promising studies were identified. Both studies were 
single center non-randomized observational studies. Study 1 evaluated the peri-
procedural complications and long-term outcomes after ASA and myectomy, and study 2 
evaluated three month follow up after both procedures.  
 
 
 
 
 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
 
For	more	information,	visit	www.prisma-statement.org. 
 
PRISMA	2009	Flow	Diagram 
 
Sc
re
en
in
g	
In
cl
u
d
ed
	
El
ig
ib
ili
ty
	
Id
en
ti
fi
ca
ti
o
n
	
Records	identified	through	database	
searching	
(n	=	97)	
Pub	Med:	“hypertrophic	
cardiomyopathy”	“alcohol	septal	
ablation”	“myectomy”	
	
Full-text	articles	assessed	
for	eligibility	
(n	=	67)	
	
Records	excluded	
Non-human	studies,	
non-English	studies,	
studies	>	15	years	
(n	=	30)	
Studies	included	in	
qualitative	analysis	
(n	=	13)	
	
Non-comparative	studies	
excluded	
	(n	=		54	)	
Studies	included	in	
quantitative	analysis		
(1	meta-analysis,	2	
comparative	studies)		
(n	=	3)	
	
Final	studies	included	
(n=2)	
	
Meta-analysis	excluded	due	to	
lack	of	statistical	significance	in	
studies	used	
(n	=1)	
	
Results 
Study # 1:  
Periprocedural Complications and Long-Term Outcome After Alcohol Septal Ablation 
Versus Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy. Steggerda et 
al.4 
 
Objective:  
To compare surgical myectomy and alcohol septal ablation (ASA) for periprocedural 
complications and long-term clinical outcome in patients with symptomatic hypertrophic 
obstructive cardiomyopathy 
 
Study design: 
This was a nonrandomized, observational study of myectomy and ASA 
procedures preformed in a Netherlands hospital between 1981 and 2010. Surgical 
myectomy was carried out beginning in 1981 and ASA was carried out beginning in 
2000. A retrospective analysis of baseline characteristics for patients who underwent 
treatment is seen below in Table 1.  
 Patients who underwent myectomy were more likely to have angina and coronary 
artery disease, while those who underwent ASA had increased septal and posterior wall 
thickness.  
 
Table 1: Baseline Patient Characteristics 
 Myectomy (n=102) ASA (n= 161) P value  
Angina 2.3 ± 0.6 2.0 ± 0.5 0.002 
Coronary a. disease 17% 5% 0.004 
Septal thickness, 
mm  
20(17-24) 21(19-24) 0.003 
Posterior wall 
thickness, mm  
14 ± 3 15 ± 4 0.01 
Gradient baseline, 
mmHg 
50 (25-75) 32 (18-75) 0.088 
 To be eligible for either procedure, all patients were required to be severely 
symptomatic despite medical therapy and all had a resting gradient of 30 mmHg or a 
provocative gradient of at least 50 mmHg. Provocation testing using a Valsalva 
maneuver, venodilators, or exercise stress testing is often required to induce the left 
ventricular outflow tract obstruction associated with HOCM.  
 Myectomy was the required procedure for patients with hypertrophic 
cardiomyopathy in addition to subvalular disease or coronary artery disease. Patients who 
were eligible for myectomy or ASA were explained the risks and benefits and were able 
to choose between the two procedures. 161 patients underwent ASA and 102 patients 
required myectomy. 
A transthoracic echocardiogram was performed in all patients before intervention 
to measure the degree of left ventricular outflow tract (LVOT) obstruction. In patients 
undergoing surgical myectomy, a transesophogeal echocardiogram was used 
intraoperatively to measure the post-surgical LVOT gradient. In patients undergoing 
ASA, the LVOT was measured invasively following the ablation procedure. Records 
were obtained from all patients who had a follow up echocardiogram to determine the last 
known ejection fraction and LVOT gradients after the procedures. 
 Periprocedural (30-day) complications were obtained through a retrospective 
analysis of hospital records. Clinical outcome and long-term survival were investigated in 
2010 using hospital records in addition to a mailed questionnaire with follow up 
telephone inquiry when necessary. Questions focused on post procedural symptoms such 
as chest pain and syncope, as well as the patients’ New York Heart Association 
functional class status (1 to 4). Hospital records were obtained for clinical events that 
required a re-admittance for heart failure or repeat cardiac intervention. For patients who 
were not alive at the time of follow up, a cause of death was obtained from records. 
All-cause mortality of both ASA and myectomy during a maximal follow-up 
period of 11 years was the primary endpoint of the study. Annual cardiac death rates, 
cerebral vascular accidents, myocardial infarctions, NYHA functional class, and heart 
failure requiring re-hospitalization were all included as secondary endpoints.  
Statistical analysis was performed using the Mann-Whitney U test and Student t 
test to compare variables between the ASA and myectomy group. The Mann-Whitney 
test was used to compare the two treatments and for analyzing the difference between the 
medians of the data sets. The Student t test was then used to determine if the two sets of 
date were significantly different. Because the sample groups in this study were 
independent, this was an appropriate statistical analysis to use.  
All cause mortality was determined using the Cox proportional hazard analysis. 
This analysis is commonly used to estimate the risk of death for an individual after taking 
into account different variables. In this particular study the baseline variables included 
age, sex, NYHA functional class, medical history and echocardiogram findings. A p-
value of less than 0.05 was considered to be statistically significant. 
 
Study results:  
Periprocedural complications (30 days) were measured and included death, CVA, 
ventricular tachycardia/fibrillation, tamponade, pacemaker implantation, and urgent 
repeat thoracotomy. The ASA group had a lower periprocedural complication frequency 
compared to the myectomy group (14% [22 of 161] versus 28% [29 of 102], p-value = 
0.004). ASA group also had a significantly shorter follow-up stay than the myectomy 
group (5 days versus 9 days, p-value = <0.001) 
Maximal follow-up duration of 11 years showed that all-cause mortality was comparable 
between ASA and myectomy groups (Figure 1). Univariate analysis was used to deal 
with only one variable at a time without taking other variables into consideration. In this 
study it demonstrated that age (per 5 years) and coronary artery disease were the only 
statistically significant predictors of all-cause mortality. Age had a hazard ratio of 1.42 
(95% CI 1.18-1.71, p-value <0.001) and coronary artery disease had a hazard ratio of 
2.96 (95% CI 1.11-7.90, p-value 0.030). These hazard ratios were used to measure how 
often death occurred in one group compared to how often it occurred in another group.  
Multivariate analysis incorporated multiple prediction variables and it showed that age 
was the only independent predictor of long-term mortality (hazard ratio 1.34, 95% CI 
1.08-1.65, p-value 0.007) 
   
 (figure 1: Survival after ASA vs Myectomy) 
 
96% of patients were still alive at follow-up and questionnaires regarding their 
symptomatic status were administered. There were no differences in CVA, MI, re-
hospitalization for heart failure, or overall symptomatic status between the ASA and 
myectomy groups. 92% of patients underwent a repeat echocardiogram during the late 
follow-up period (3.9 ± 4.7 years) to measure the LVOT gradient.  Patients who received 
ASA had a higher gradient at late follow-up than the myectomy patients. This is 
contrasted to the decreased gradient post procedure in the ASA group compared to the 
myectomy group. There were a total of 10 reinterventions preformed after ASA due to a 
significant residual gradient following the procedure but only 1 intervention was 
necessary in the surgical myectomy group. Table 2 summarizes significant periprocedural 
complications and clinical outcomes between the two procedure groups. 
 
 
 
 
 
 
 
 
 
Table 2: Complications & Outcomes 
 Myectomy (n=102) ASA (n=161) P value 
Periprocedural 
complications  
28% 14% 0.004 
Length of hospital 
stay, days 
9 (6-12) 5 (4-6) <0.001 
Post-procedural 
gradient, mmHg 
12( 8-20) 10 (0-20) <0.001 
Late follow up 
gradient, mmHg 
9 (4-10) 10 (7-19) 0.003 
Reintervention 
within long term 
follow up 
1% (1) 6.3% (10) 0.055 
 
Study #2:  
Outcome of Patients with Hypertrophic Obstructive Cardiomyopathy After Percutaneous 
Transluminal Septal Myocardial Ablation and Septal Myectomy Surgery. Qin et al.5 
 
Objective: 
To evaluate the subjective and objective follow-up results in patients undergoing alcohol 
septal ablation and surgical myectomy for treatment of drug refractory hypertrophic 
obstructive cardiomyopathy (HCOM).  
 
Study design 
This was a non-randomized cohort study of 51 symptomatic patients with 
hypertrophic obstructive cardiomyopathy. The diagnosis of HOCM was based on the 
presence of a hypertrophied, non-dilated left ventricle.  All patients were symptomatic 
and presented with angina (42%), dyspnea (78%), or syncope (24%), and a New York 
Heart Association (NYHA) Functional class of at least III. Additionally, patients were 
refractory to drug treatment and had a left ventricular outflow tract (LVOT) gradient ≥50 
mmHg. 
All 51 patients were informed of the two treatment methods, and gave informed 
consent prior to the procedures. Twenty-six of the 51 patients underwent surgical 
myectomy, and twenty-five underwent alcohol septal ablation. All patients had a 
conventional two-dimensional ECHO and a doppler ECHO performed before the 
procedure, immediately after the procedure, and at 3 month follow up. A transesophageal 
echocardiogram TEE was only performed if suitable images could not be obtained prior 
to the procedure. The interventricular septum thickness, the posterior wall thickness, and 
the LV left ventricular ejection fraction were all assessed prior to undergoing a 
procedure.  Additionally, the peak pressure gradient through the LVOT was estimated 
using the Bernoulli equation. This equation estimates the speed of a liquid based on the 
inverse relationship between velocity and pressure as it moves from point A to point B. 
Both procedures were deemed successful when the resting pressure gradient (PG) 
was less than 16 mm Hg, or the percentage of pressure gradient reduction was more than 
50%. The reduction was calculated using:  
(PG before procedure- PG after procedure) x 100% 
  (PG before procedure) 
After discharge following these procedures, all 51 patients underwent a clinical 
evaluation by a cardiologist, which included assessment of NYHA functional class. 
Follow up for myectomy was 128 ± 84 days, and follow up for ASA was 117 ± 36 days.  
 
Study 2 Results  
Patients who underwent alcohol septal ablation were significantly older (mean age 
63 ± 14 years) and tended to have more comorbid conditions that could increase the risk 
of surgery compared to those who underwent surgical myectomy (mean age 48 ± 13 
years). Additionally, 58% of patients undergoing both procedures were on beta-blockers, 
30% on calcium channel blockers, and 12% on both at the time of the procedure. There 
was no difference in the intraventricular septal thickness between the two groups before 
the procedures, but the interventricular sepum (IVS) thickness was significantly reduced 
at follow up (2.3± 0.4 cm vs. 1.9 ± 0.4 for ASA compared to 2.4± 0.6 cm vs. 1.7 ± 0.2 cm 
for myectomy).  
In those patients undergoing ASA which was referred to as percutaneous 
transluminal septal myocardial ablation (PTSMA) in this study, the resting pressure 
gradient decreased from 64 ± 39 mmHg to 28 ± 29 mmHg after the procedure, and to 24 
± 19 mmHg at 3 month follow up. Twenty-two of the 25 patients had a post procedure 
PG of <16mmHg or a >50% reduction in PG at follow up, deeming the procedure 
successful.  In those undergoing myectomy, the resting pressure gradient decreased from 
62 ± 43 mmHg to 7 ± 7 mmHg after the procedure, and to 11 ± 6 mmHg at 3 month 
follow up. One hundred percent of the ASA patients had post procedure PG of <16mmHg 
or a >50% reduction in PG at follow up, deeming the procedure successful. Between the 
post procedure and the follow up period, four patients had resting PG increase slightly, 
but it was still much lower than the PG before the procedure.  At the 3-month follow-up 
the PG was completely eliminated in 81% of patients receiving myectomy, while only 
52% of of ASA patients showed a PG <16mmHg.  These results are seen in Figure 3.  
 
New York Functional Class was assessed both before and after treatment. This is a 
standard classification used to assess the degree of heart failure. Class one patients have 
cardiac disease but no symptoms, class two patients have mild symptoms, class three 
patients have marked limitation in activity due to symptoms, and class four patients have 
severe limitations.6 All 51 patients in this study had a NYHA functional class of ≥3.  
ASA patients had an average class of 3.5 ± 0.5 that was decreased to 1.9 ± 0.7 after the 
procedure. Myectomy patients had an average class of 3.3 ± 0.5 that was decreased to 1.5 
± 0.7 after the procedure. Both of these values had a p value of < 0.001. These results are 
seen in Figure 4.  
 There were no deaths reported within the 3 months following both treatments. After 
undergoing ASA, 9 patients had complete right bundle branch block, and two patients 
had complete left bundle branch block. Sixteen patients had left bundle branch block after 
undergoing myectomy. The mean hospital stay for ASA patients was 5.6 ± 2.3 days 
compared to 8.1 ± 3.5 days for the myectomy patients. Pacemakers were required in six 
patients who underwent ASA and in 2 patients who underwent myectomy. These results 
are seen in Table 3.  
Table 3: Complications & Outcomes 
 
In general, both alcohol septal ablation and surgical myectomy were found to improve 
NYHA functional class, reduce the hypertrophied interventricular septum, and decrease 
LVOT obstruction. Patients undergoing myectomy had a greater reduction in LVOT PG, 
and those undergoing alcohol septal ablation had a shorter hospital stay.  
 
Discussion 
According to the two studies reviewed, clinical outcomes for HOCM patients are 
comparable following both ASA and myectomy. Because ASA is a fairly new procedure 
compared to myectomy, additional studies need to be done to arrive at a more definitive 
conclusion.  
Study 1 is the first to analyze both periprocedural (30 day) complications as well 
as long-term (11 years) outcomes of the two treatments for HOCM. Previous studies 
(such as Study 2, Qin et al.) did not address long-term results. Strengths of Study 1 
included comparable clinical baseline characteristics in the ASA and myectomy groups 
except for concomitant coronary artery disease and a slight difference in the degree of left 
ventricular hypertrophy. Average age was also similar in both groups. Follow-up was 
another strength of this study, as questionnaires were administered to 96% of the patients. 
Telephone follow up was used to ensure accurate information when needed. 
The fact that this was a non-randomized, observational study was a limitation 
however a randomized control trial would be nearly impossible to conduct with HOCM 
patients. The choice between an ablation and a myectomy is a personal one and patients 
should have the right to choose the procedure that they feel is best for them and is most 
appropriate procedure based on their individual condition. This study was conducted in 
the Netherlands therefore may not be representative of the general HOCM population. A 
potential source of bias was the fact that ASA procedures involved in this study began in 
2000, whereas the myectomy procedures dated as far back as 1981.  Additionally, bias 
may have resulted because certain baseline characteristics were specific to each 
treatment. Those with angina and coronary artery disease were more likely to undergo 
myectomy while patients with posterior wall thickness were slightly increased in those 
who underwent ASA. Furthermore, certain patients were required to have myectomy 
while other patients were given the choice between the two procedures.  
Study 1 concluded that long term symptomatic improvement and long-term 
survival were comparable between the ASA and myectomy groups. ASA was shown to 
be associated with less periprocedural complications than surgical myectomy, which had 
not been reported in previous studies. The complications with myectomy, however, were 
attributed to the more invasive nature of the procedure, and were not associated with a 
worse long-term outcome. The surgical myectomy procedure also resulted in an increased 
hospital stay compared to the less invasive alcohol septal ablation. 
Strengths of Study 2 include systematic screening and follow up on all patients 
with ECHO right after the procedure and at 3-month follow-up. The same parameters 
were measured before and after the procedures were completed.  
The two groups were dissimilar in many aspects. Older patients with significant 
comorbid conditions underwent alcohol septal ablation, while younger patients had 
myectomy. Follow-up was fairly short, and long-term results are unknown at this point.  
Additionally, there was no criterion for dividing the patients into the two procedures, 
treatment was chosen based on patient and physician preference. The sample size was 
small therefore a student t test was used which compared the average of the study groups 
to find significant differences.7 A p value of < 0.01 was considered statistically 
significant, and a Chi squared test was used to compare success rates and complications 
between the two study groups. All parameters measured in this study were statistically 
significant (p value < 0.01) with the exception of the larger end diastolic diameter of the 
LV in ASA group before the procedure (p= 0.03), and the end diastolic diameter of the 
LV increasing after ASA (p= 0.01) and after myectomy (p= 0.06).  Additionally, the 
presence of bundle branch blocks after procedure (p> 0.05), and permanent pacemakers 
required (p>0.05) were not statistically significant.  
Study 2 concluded that both ASA and surgical myectomy reduce the 
hypertrophied interventricular septum, decrease pressure gradient across the left ventricle 
and improve NYHA functional class, thereby reducing symptoms. Those who underwent 
ASA had a shorter hospital stay compared to those who underwent myectomy, but 
patients who underwent myectomy had a greater reduction in PG,   
 
 
Conclusion 
In summary, long term survival and symptomatic improvement after both ASA and 
myectomy is comparable. ASA is associated with decreased length of hospital stay 
following the procedure as well as a decreased rate of periprocedural complications. 
Because ASA is a less invasive procedure than surgical myectomy, it should be 
considered when deciding on HOCM surgical treatment. As convenient and less invasive 
as it is, it’s important to note that ASA will not be replacing surgical myectomy in the 
treatment of symptomatic HOCM patients. Surgical myectomy may be the necessary 
method if the patient has multivessel coronary artery disease or septal anatomy that is 
unsuitable for alcohol ablation. For our clinical scenario, the 55-year-old patient should 
meet with his cardiologist and surgeon to ensure that his personal preference is taken into 
consideration in addition to his individual cardiovascular history.  
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